Remdesivir-Induced Bradycardia

Kanagala, Sai Gautham; Dholiya, Hardeep; Jhajj, Poonam; Patel, Meet A; Gupta, Vasu; Gupta, Sachin; Wu, Shiau-Ing; Jain, Rohit

doi:10.14423/smj.0000000000001519

Cited by 6 publications

(5 citation statements)

References 13 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the mean age in the group with complications was significantly higher than the group without complications. These results support the findings of previous research that demonstrated an increased prevalence of bradycardia [28] and other cardiac complications [26,29] with Remdesivir in older persons [22]. Older patients who develop cardiac events linked to Remdesivir may have age-related cardiovascular abnormalities, especially in the conduction system [30].…”

Section: Discussionsupporting

confidence: 90%

“…In one observational research with over 6500 COVID-19 patient reports, Remdesivir caused bradycardia as the most common cardiac adverse effect [21]. Remdesivir-induced bradycardia most likely results from sinus node and mitochondrial malfunction [22]. Remdesivir, as an inhibitor of viral RNA polymerases, has antiviral properties, but it also interacts with the human mitochondrial RNA polymerase, inhibiting it and resulting in mitochondrial malfunction.…”

Section: Discussionmentioning

confidence: 99%

“…Adenosine reduces the automaticity at the sinus node of the heart. It does this by acting on the SA node via the A1 (adenosine) receptor [22,24].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study

Abedipour,

Mirzaei,

Ansari

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

Background There have been reports of serious side effects of Remdesivir, including cardiovascular complications. The present study aimed to determine the adverse cardiovascular effects of Remdesivir and the factors affecting them in COVID-19 patients. Methods The patients were classified into two groups: those receiving Remdesivir without cardiac complications and those receiving Remdesivir with cardiovascular complications. After reviewing the patientʼs medical records, the relationship of some factors with the incidence of adverse cardiovascular effects was measured. Results Chi-square test showed that the distribution of complications in men was significantly higher than in women (P=0.001). The independent t-test revealed that the mean age in the group with complications was significantly higher than the group without complications (P=0.013). Fisherʼs exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in the groups with and without heart complications. Conclusion Our findings indicated that most of the COVID-19 patients suffered from sinus bradycardia, and the distribution of complications was more pronounced in men than in women. The mean age in the group with complications was higher than the group without complications. Smoking was found to be associated with the occurrence of cardiovascular complications and the mean changes of Bilirubin and ALKP before and after treatment were significantly different in the groups with and without cardiovascular complications.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study

Abedipour,

Mirzaei,

Ansari

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

show abstract

“…107 Entre los efectos secundarios más comunes del Remdesivir, se encuentran aquellos en la esfera cardiovascular, 108 siendo la bradicardia el más frecuente, aunque también puede presentarse hipotensión, arritmias tipo fibrilación auricular, prolongación del intervalo QT, ensanchamiento del complejo QRS, Torsade de pointes. 108,109 Comentarios: La aprobación del Remdesivir a pesar de ser útil en circunstancias determinadas, conllevó a la sobreutilización del medicamento. 59 La evidencia sobre su uso aún permanece limitada.…”

Section: Colchicinaunclassified

Daño Colateral en el Tratamiento de Pacientes con COVID-19.

Isea Dubuc,

Morillo Silvera,

Carballo Ocanto

et al. 2023

Rev Cien CMDLT

View full text Add to dashboard Cite

A finales del año 2019 se desarrolla la pandemia de COVID-19, una enfermedad infecciosa causada por un virus previamente no identificado, que produjo consecuencias catastróficas a nivel mundial. Los reportes epidemiológicos mostraron que después de adquirir la infección, la mayoría de las personas experimentan enfermedad leve sin complicaciones, sin embargo, algunos de los pacientes, requirieron hospitalización. Durante los años 2020 a 2022, fueron evaluados en nuestra institución cerca de 1800 pacientes. Dentro del arsenal terapéutico, fueron utilizados equipos de ventilación mecánica invasiva y no invasiva y medicamentos que incluyeron: antivirales, oxígeno, sedantes, antibióticos, anticoagulantes, protectores gástricos, analgésicos, hipolipemiantes, antiarrítmicos, diuréticos, hipotensores, antipsicóticos, analgésicos, hemoderivados, colchicina, esteroides, fibrinolÍticos y anticuerpos contra interleukina 6: tocilizumab, suplementos vitamínicos entre otros. De igual manera fueron utilizados, catéteres venosos y arteriales, tubos endotraqueales, sondas nasogástricas y de aspiración, tubos de drenaje, sondas vesicales y colocación en posición prona en aquellos pacientes con hipoxemia severa. La terapéutica no estuvo exenta de complicaciones. Nuestro objetivo es hacer del conocimiento a la comunidad médica de algunos pormenores de estos eventos ocurridos tanto en la sala de hospitalización como en la unidad de cuidados intensivos COVID, no atribuidos a efectos directos perjudiciales del virus, sino, a las consecuencias de los tratamientos aplicados.

show abstract

“…In recent research, there has been considerable interest in investigating the association between remdesivir treatment and the occurrence of bradycardia [8]. Although remdesivir has shown efficacy in treating COVID-19, it is crucial to explore its potential cardiovascular effects, identify risk factors that may result in bradycardia, and gain a deeper understanding of the underlying mechanism.…”

Section: Introductionmentioning

confidence: 99%

Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis

Ai,

Chang,

Yang

2023

JCM

View full text Add to dashboard Cite

Background: The efficacy of remdesivir in reducing disease severity among COVID-19-infected patients has been established, but concerns have emerged regarding the potential side effects of bradycardia. The aim of this study was to investigate the association between remdesivir-induced bradycardia and mortality, while also identifying the related risk factors. Materials and methods: The PubMed/Medline, Cochrane Central and ClinicalTrials.gov databases were searched. Randomized controlled trials and prospective or retrospective cohort studies were included (through 14 July 2023). The random-effects model was implemented using Comprehensive Meta-Analysis software version 3.0 to examine the outcomes. Results: A total of 12 prospective or retrospective studies involving 7674 patients were analyzed. The primary outcomes revealed a significant association between remdesivir administration and bradycardia development (Odds ratio = 2.556, 95% CI = 2.049–3.188, p < 0.001). However, no statistically significant increase in the mortality rate was observed among patients with bradycardia during remdesivir treatment (Odds ratio = 0.872, 95% CI = 0.483–1.576, p = 0.651). The secondary outcome demonstrated a significant association between chronic kidney disease (CKD) and remdesivir-induced bradycardia (OR: 1.251, 95% CI: 1.003–1.561, p = 0.047). Moreover, patients with obesity (OR = 1.347, 95% CI = 1.098–1.652, p = 0.004) were more likely to experience remdesivir-induced bradycardia. Conclusions: Although a higher risk of bradycardia occurred during remdesivir treatment, the occurrence of remdesivir-induced bradycardia did not lead to higher mortality. Our study also identified patients with obesity and CKD as high-risk subgroups for experiencing bradycardia during remdesivir treatment.

show abstract

Remdesivir-Induced Bradycardia

Cited by 6 publications

References 13 publications

Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study

Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study

Daño Colateral en el Tratamiento de Pacientes con COVID-19.

Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About